Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses-Immunometabolism-CSCIED科技核心评价数据库-手机版

Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses

Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses

ES评分 0 浏览量：1045 下载量：0

DOI	10.1097/IN9.0000000000000019
刊名	Immunometabolism IJ
年，卷(期)	2023, 5(1)
作者	Peeters, Marlies J. W.; Desler, Claus; Straten, Per Thor,
作者单位	[Peeters, Marlies J. W.; Straten, Per Thor] Copenhagen Univ Hosp Herlev, Natl Ctr Canc Immune Therapy, Dept Oncol, Copenhagen, Denmark; [Desler, Claus] Univ Copenhagen, Ctr Hlth Aging, Dept Cellular & Mol Med, Copenhagen, Denmark; [Straten, Per Thor] Univ
摘要	It has been well established that the metabolism of T cells is integral to their functionality. If a T cell cannot generate enough energy or building blocks, it will not be able to exert its cytotoxic properties to eliminate pathogens and cancer cells. Impairment of mitochondrial oxidative phosphorylation is a well-known disruptor of T cell activation. Dihydroorotate dehydrogenase (DHODH) is a rate-limiting component of the de novo synthesis of pyrimidines and its activity is dependent on functional mitochondrial oxidative phosphorylation. In this regard, DHODH inhibitors have long been used in clinical settings for the treatment of autoimmune diseases, as they potently inhibit lymphocyte proliferation. The exact mode-of-action of these inhibitors in T lymphocytes is not yet exactly understood. In this review, we briefly discuss the critical role of mitochondria in T cell functionality. We also describe how de novo pyrimidine biosynthesis is linked to mitochondrial activity. Finally, we summarize our current knowledge of how mitochondrial-linked de novo pyrimidine biosynthesis modulates T cell responses.
Abstract	It has been well established that the metabolism of T cells is integral to their functionality. If a T cell cannot generate enough energy or building blocks, it will not be able to exert its cytotoxic properties to eliminate pathogens and cancer cells. Impairment of mitochondrial oxidative phosphorylation is a well-known disruptor of T cell activation. Dihydroorotate dehydrogenase (DHODH) is a rate-limiting component of the de novo synthesis of pyrimidines and its activity is dependent on functional mitochondrial oxidative phosphorylation. In this regard, DHODH inhibitors have long been used in clinical settings for the treatment of autoimmune diseases, as they potently inhibit lymphocyte proliferation. The exact mode-of-action of these inhibitors in T lymphocytes is not yet exactly understood. In this review, we briefly discuss the critical role of mitochondria in T cell functionality. We also describe how de novo pyrimidine biosynthesis is linked to mitochondrial activity. Finally, we summarize our current knowledge of how mitochondrial-linked de novo pyrimidine biosynthesis modulates T cell responses.
关键词	T cell metabolism; T cell activation; de novo pyrimidine synthesis; mitochondrial respiration and oxidative respiration
KeyWord	T cell metabolism; T cell activation; de novo pyrimidine synthesis; mitochondrial respiration and oxidative respiration
基金项目
页码	1-5

参考文献
相关文献

[1]. Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018;36:461–88. doi: 10.1146/annurev-immunol-042617-053019.

[2]. Tan H, Yang K, Li Y, et al. Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation. Immunity. 2017;46(3):488–503. doi: 10.1016/j.immuni.2017.02.010.

[3]. Baixauli F, Acín-Pérez R, Villarroya-Beltrí C, et al. Mitochondrial respiration controls lysosomal function during inflammatory t cell responses. Cell Metab. 2015;22(3):485–98. doi: 10.1016/j.cmet.2015.07.020.

[4]. Sena LA, Li S, Jairaman A, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. 2013;38(2):225–36. doi: 10.1016/j.immuni.2012.10.020.

[5]. Chang C-H, Curtis JD, Maggi LB, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–51. doi: 10.1016/j.cell.2013.05.016.

[6]. Milasta S, Dillon CP, Sturm OE, et al. Apoptosis-inducing-factor-dependent mitochondrial function is required for T cell but not B cell function. Immunity. 2016;44(1):88–102. doi: 10.1016/j.immuni.2015.12.002.

[7]. Buck MD, O’Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015;212(9):1345–60. doi: 10.1084/jem.20151159.

[8]. Sullivan LB, Gui DY, Hosios AM, et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162(3):552–63. doi: 10.1016/j.cell.2015.07.017.

[9]. Shi LZ, Wang R, Huang G, et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367–76. doi: 10.1084/jem.20110278.

[10]. Angelin A, Gil-de-Gómez L, Dahiya S, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25(6):1282–1293.e7. doi: 10.1016/j.cmet.2016.12.018.

[11]. Desdín-Micó G, Soto-Heredero G, Mittelbrunn M. Mitochondrial activity in T cells. Mitochondrion. 2018;41:51–7. doi: 10.1016/j.mito.2017.10.006.

[12]. van der Windt GJW, Everts B, Chang CH, et al. Mitochondrial respiratory capacity is a critical regulator of CD8 + T cell memory development. Immunity. 2012;36(1):68–78. doi: 10.1016/j.immuni.2011.12.007.

[13]. Fairbanks LD, Bofill M, Ruckemann K, et al. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J Biol Chem. 1995;270(50):29682–9.

[14]. Sykes DB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 2018;22(11):893–8. doi: 10.1080/14728222.2018.1536748.

[15]. Desler C, Lykke A, Rasmussen LJ. The effect of mitochondrial dysfunction on cytosolic nucleotide metabolism. J Nucleic Acids. 2010;2010:701518. doi: 10.4061/2010/701518.

[16]. Bader B, Knecht W, Fries M, et al. Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase. Protein Expr Purif. 1998;13(3):414–22. doi: 10.1006/prep.1998.0925.

[17]. Madak JT, Bankhead A, Cuthbertson CR, et al. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195:111–31. doi: 10.1016/j.pharmthera.2018.10.012.

[18]. Klotz L, Eschborn M, Lindner M, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 2019;11(490):eaao5563. doi: 10.1126/scitranslmed.aao5563.

[19]. Rückemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273(34):21682–91. doi: 10.1074/jbc.273.34.21682.

[20]. Martin E, Palmic N, Sanquer S, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510(7504):288–92. doi: 10.1038/nature13386.

[21]. Quéméneur L, Gerland L-M, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170(10):4986–95. doi: 10.4049/jimmunol.170.10.4986.

[22]. Dimitrova P, Skapenko A, Herrmann ML, et al. Restriction of de novo pyrimidine biosynthesis inhibits TH1 cell activation and promotes TH2 cell differentiation. J Immunol. 2002;169(6):3392–9. doi: 10.4049/jimmunol.169.6.3392.

[23]. Quéméneur L, Beloeil L, Michallet M-C, et al. Restriction of de novo nucleotide biosynthesis interferes with clonal expansion and differentiation into effector and memory CD8 T cells. J Immunol. 2004;173(8):4945–52. doi: 10.4049/jimmunol.173.8.4945.

[24]. Pinschewer DD, Ochsenbein AF, Fehr T, et al. Leflunomide-mediated suppression of antiviral antibody and T cell responses: differential restoration by uridine. Transplantation. 2001;72(4):712–9. doi: 10.1097/00007890-200108270-00026.

[25]. Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide- mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76(5):950–60. doi: 10.1189/jlb.0504308.

[26]. Chong ASF, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation. 1996;61(1):140–5. doi: 10.1097/00007890-199601150-00026.

[27]. Forrest TL, Ware RE, Howard T, et al. Novel mechanisms of brequinar sodium immunosuppression on T cell activation. Transplantation. 1994;58(8):920–6. doi: 10.1097/00007890-199410270-00011.

[28]. Xu X, Williams JW, Shen J, et al. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium. J Immunol. 1998;160(2):846–53.

[29]. Peeters MJW, Aehnlich P, Pizzella A, et al. Mitochondrial-linked de novo pyrimidine biosynthesis dictates human T-cell proliferation but not expression of effector molecules. Front Immunol. 2021;12:718863. doi: 10.3389/fimmu.2021.718863.

[30]. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275(2):1043–9.

[31]. Xuan J, Ren Z, Qing T, et al. Mitochondrial dysfunction induced by leflunomide and its active metabolite. Toxicology. 2018;396-397:33–45. doi: 10.1016/j.tox.2018.02.003.

[32]. Yu M, Nguyen ND, Huang Y, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;5(16):e126915. doi: 10.1172/jci.insight.126915.

引用本文

Peeters, Marlies J. W.; Desler, Claus; Straten, Per Thor. Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses [J]. Immunometabolism. 2023; 5; (1). 1 - 5.

文献评论

相关学者

相关机构